Palisade Bio (NASDAQ:PALI) Downgraded to “Sell” Rating by Wall Street Zen

Palisade Bio (NASDAQ:PALI) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other research analysts have also recently issued reports about the stock. Citigroup restated a “buy” rating on shares of Palisade Bio in a report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $16.00.

Palisade Bio Stock Performance

Shares of NASDAQ PALI opened at $1.83 on Friday. Palisade Bio has a fifty-two week low of $0.53 and a fifty-two week high of $2.59. The company has a market cap of $272.67 million, a price-to-earnings ratio of -0.86 and a beta of 1.54. The business’s 50 day moving average price is $1.90 and its 200-day moving average price is $1.21.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.06). Sell-side analysts predict that Palisade Bio will post -12.43 earnings per share for the current year.

Institutional Investors Weigh In On Palisade Bio

An institutional investor recently raised its position in Palisade Bio stock. Armistice Capital LLC boosted its position in shares of Palisade Bio, Inc. (NASDAQ:PALI) by 37.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 144,764 shares of the company’s stock after acquiring an additional 39,397 shares during the period. Armistice Capital LLC owned 3.29% of Palisade Bio worth $99,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.